tirzepatide obstructive sleep apnea ✨ FDA Approves for Apnea! ✨ A breakthrough in treating moderate to severe OSA—tirzepatide (Zepbound) is the first-ever medication approved by the FDA for this condition in adults with Frontiers | GLP-1/GIP dual agonist

The dual mechanism of BPC-157s vascular stabilization and TB-500s migratory promotion makes it an attractive candidate in vascularization studies

I gave birth at like 230lbs and then didnt emerge from the fog that was my post-partum depression until a year later and another 30lbs heavier

In this blog post, we evaluate recent literature regarding the usage of methylene blue for attenuation of adverse effects related to TBI and other brain injuries

By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery. The study is called the Cessation or Reduction of Alcohol Consumption in Veterans trial

Evercore ISI estimated net prices for Zepbound to be $650 per month, according to an analyst note to clients on Tuesday